AbbVie v. Sun Pharma: Elagolix ANDA Blocked by Consent Injunction in 137 Days
AbbVie, Inc. filed suit in the Delaware District Court against Sun Pharmaceutical Industries over ANDA 215804, a generic version of ORILISSA® (elagolix sodium oral tablets). The parties reached a stipulated consent order within 137 days, enjoining Sun from commercialising the generic product for the life of both asserted patents.
Hatch-Waxman consent order locks out elagolix generics for patent life
On 5 February 2024, AbbVie, Inc. filed a Hatch-Waxman infringement action in the District of Delaware against Sun Pharmaceutical Industries, Inc., asserting that Sun’s filing of ANDA 215804 — seeking approval of generic elagolix sodium oral tablets at 150 mg and 200 mg base equivalents — constituted a technical act of infringement of US11690845B2 and US11690854B2 under 35 U.S.C. § 271(e)(2)(A). Elagolix sodium is the active ingredient in ORILISSA®, AbbVie’s branded therapy for endometriosis-associated pain.
The case closed on 21 June 2024 via a stipulated consent order signed by Judge Jennifer L. Hall. The order formally adjudges Sun’s ANDA filing as an act of infringement of both patents and enjoins Sun — along with its officers, agents and affiliates — from manufacturing, using, selling or importing the ANDA 215804 products in the United States for the full life of either patent, including any extensions or paediatric exclusivities, absent a licence from AbbVie. Remaining claims and defences were dismissed without prejudice, and both parties expressly waived their right to appeal.
Resolution in just 137 days is notably swift for Hatch-Waxman litigation and suggests the parties reached agreement before substantive discovery or claim construction proceedings. The public record does not disclose the commercial terms — if any — underlying the stipulation, including whether a future launch date was negotiated. The carve-out preserving claims relating to other products beyond ANDA 215804 elagolix tablets indicates the parties deliberately left the door open for future disputes over different formulations or indications covered by the same patents.
Filing to Dismissed without Prejudice in 137 days
137-day resolution — well below the median ANDA Hatch-Waxman trial timeline of 2–3 years
Consent order and injunction: what the stipulated ruling means for both parties
Stipulated consent order: infringement admitted, injunction entered by agreement
Under Hatch-Waxman, the filing of an ANDA with a Paragraph IV certification is itself a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A). Here, both parties stipulated that Sun’s filing of ANDA 215804 constituted infringement of both asserted patents. The court entered the order on consent, meaning no merits trial occurred — the legal finding of infringement and the resulting injunction reflect an agreed resolution, not a contested judicial determination.
Consent order — no merits trialAbbVie secures patent-life exclusivity for ORILISSA® elagolix tablets
The consent order delivers AbbVie a durable enforcement result: Sun is enjoined from commercialising any ANDA 215804 elagolix sodium product for the life of US11690845B2 and US11690854B2, including all extensions and paediatric exclusivities. The without-prejudice dismissal of remaining claims preserves AbbVie’s ability to bring future actions regarding other elagolix products or ANDA configurations, strengthening its exclusivity posture across the elagolix franchise.
Patent-life injunction securedSun Pharma enjoined from launching generic elagolix for patent life
Sun is barred from manufacturing, selling, or importing the 150 mg and 200 mg elagolix sodium tablets described by ANDA 215804 until both patents expire, unless all claims of both patents are found invalid or unenforceable by a final, unappealable court decision. Sun expressly waived its appellate rights under this order. However, the without-prejudice carve-out means Sun retains standing to challenge the patents or pursue different product configurations in future proceedings.
Launch enjoined; appeal waivedSwift settlement reinforces branded elagolix exclusivity against ANDA challengers
A 137-day Hatch-Waxman resolution — particularly one that results in a formal infringement adjudication and patent-life injunction — signals robust patent coverage for the elagolix sodium formulations. Other ANDA filers targeting ORILISSA® will likely take note: AbbVie obtained a consent injunction without proceeding to trial, suggesting confidence in the strength of both patents. The carve-out for non-ANDA-215804 products may indicate additional ANDA activity is anticipated.
Strong exclusivity signal for elagolix IPFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Pharmaceutical innovator — holder of US11690845B2 and US11690854B2 (ORILISSA® elagolix sodium)Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for elagolix sodium oral tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is notable for its precision: it formally adjudges ANDA filing as infringement under § 271(e)(2)(A) — creating a record of infringement — while dismissing all remaining claims without prejudice. The without-prejudice posture means Sun retains the ability to litigate validity and enforceability in any future action concerning different products. Both parties’ express waiver of appellate rights makes the injunction immediately final, eliminating uncertainty typically associated with post-order motions practice.
US11690845B2 & US11690854B2 — Elagolix Sodium Oral Tablet Formulations
US11690845B2 and US11690854B2 both protect elagolix sodium oral tablet formulations — the active pharmaceutical ingredient underlying AbbVie’s ORILISSA® brand. Elagolix is a GnRH receptor antagonist indicated for the management of moderate-to-severe endometriosis-associated pain. Both patents were filed under application numbers US17/004817 and US17/047871 respectively, placing them squarely within the post-2020 patent filing period and suggesting meaningful remaining patent term at the time of the litigation.
For the branded pharmaceutical sector, these patents represent a critical layer of ORILISSA® exclusivity beyond any composition-of-matter protection on elagolix itself. Their assertion in Hatch-Waxman proceedings — and the resulting consent injunction — confirms AbbVie’s strategy of building layered formulation patent protection to extend commercial exclusivity. Competitors and generic manufacturers developing elagolix ANDAs must conduct thorough FTO analysis against both patents, including any continuation or divisional applications that may be pending in the same patent families.
Should your ANDA or elagolix product trigger an FTO against US11690845B2 and US11690854B2?
Any generic or branded manufacturer developing elagolix sodium oral tablets — particularly 150 mg or 200 mg dosage forms — should treat US11690845B2 and US11690854B2 as active enforcement risks. This case demonstrates AbbVie’s willingness to file suit promptly upon ANDA submission and to secure injunctive relief by consent before trial. R&D and regulatory teams considering NDA supplements or new elagolix formulations should also assess whether related patent family members extend coverage beyond the specific ANDA 215804 product configuration.
PatSnap Eureka’s FTO Search Agent enables rapid landscape analysis across US11690845B2, US11690854B2, and their patent families — identifying claim scope, prosecution history, and related pending applications. Eureka can also surface other ANDA-stage patents AbbVie holds in the elagolix space, helping IP and regulatory teams model launch risk timelines before submitting a Paragraph IV certification.
Run a freedom-to-operate analysis on US11690845B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA infringement cases in the Delaware District Court
Explore Hatch-Waxman ANDA infringement actions in the Delaware District Court involving branded pharmaceutical formulation patents and consent injunction outcomes.
What this case signals for the branded pharma and ANDA IP landscape
AbbVie’s rapid consent injunction over elagolix carries practical lessons for both branded and generic pharma IP teams.
Consent orders can deliver patent-life injunctions without trial risk
AbbVie obtained a full patent-life injunction in under five months without proceeding through claim construction or trial. For branded pharma patent holders facing Hatch-Waxman ANDA challenges, early negotiation — even without disclosed commercial terms — can lock in durable exclusivity faster and with less litigation cost than contested proceedings.
Without-prejudice dismissal preserves future enforcement options strategically
The explicit carve-out for non-ANDA-215804 elagolix products is a deliberate drafting choice. It signals AbbVie anticipates further ANDA filings or different formulation challenges and has preserved its ability to bring fresh infringement actions. Generic filers in the elagolix space should treat this order as a marker, not a ceiling, of AbbVie’s enforcement intent.
AbbVie v Sun — key questions answered
The Delaware District Court entered a stipulated consent order on 21 June 2024 adjudging that Sun’s filing of ANDA 215804 was a technical act of infringement of US11690845B2 and US11690854B2 under 35 U.S.C. § 271(e)(2)(A), and enjoining Sun from commercialising generic elagolix sodium oral tablets for the full life of both patents. Remaining claims were dismissed without prejudice.
AbbVie asserted US11690845B2 (application US17/004817) and US11690854B2 (application US17/047871), both covering elagolix sodium oral tablet formulations underlying the ORILISSA® branded product indicated for endometriosis-associated pain.
In this case, the without-prejudice dismissal of remaining claims means Sun retains the right to challenge the validity or enforceability of both patents in any future litigation, provided that future action concerns a product other than the elagolix sodium oral tablets described specifically by ANDA 215804. The infringement adjudication itself, however, is final.
No. The stipulated consent order expressly states that both AbbVie and Sun Pharmaceutical Industries each waived any right to appeal or otherwise move for relief from the order. This waiver makes the injunction immediately final without further appellate review.
Sun Pharma is enjoined from manufacturing, using, offering to sell, selling within the United States, or importing the generic elagolix sodium oral tablet products described by ANDA 215804 (150 mg and 200 mg base equivalents) for the full life of US11690845B2 and US11690854B2, including any patent term extensions and paediatric exclusivities. The only exception is if all claims of both patents are found invalid or unenforceable by a final, non-appealable court decision.
PatSnap Eureka searches patents and litigation data to answer instantly.